Federal Circuit Rules Against Owl Pharma In Patent Dispute Over Prostate Cancer Drug
The Federal Circuit has ruled against Ohio-based generic drug manufacturer Owl Pharmaceutical, preventing the company from making a copycat version of prostate cancer drug Lupron Depot....To view the full article, register now.
Already a subscriber? Click here to view full article